Online inquiry

IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7529MR)

This product GTTS-WQ7529MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CLDN18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001002026.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51208
UniProt ID P56856
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7529MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4678MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ2561MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ13946MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ9369MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ13523MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ10950MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ13284MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ10590MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW